Fumagillol Carbamate Polymorphs for Stable Therapeutic Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical application of fumagillin and its derivatives is limited by toxicity, and the formation of stable intermediates for conjugating polymers is hindered by self-condensation and hydrolysis issues, along with difficulties in removing impurities covalently bonded to the polymer backbone.
Innovation Solution
The development of stable, pure polymorphs of fumagill-6-yl N-(trans-4-aminocyclohexyl)carbamate salts, such as benzenesulfonic acid and hydroxynaphthoic acid salts, which can be used as intermediates for polymer-conjugated derivatives or as therapeutic agents, with specific characterization by X-ray powder diffraction patterns and thermal analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fumagillin derivatives are used as therapeutic agents, then therapeutic effect is improved, but toxicity increases
Solution Approach 1:
The fumagillin molecule is divided into separate functional components: the fumagillol core is conjugated to polymer carriers, while the cytotoxic warhead is separated and controlled through conditional activation mechanisms. This segmentation allows the therapeutic agent to be delivered to target sites without premature toxicity activation.
Solution Approach 2:
Polymer conjugates serve as intermediaries that carry the fumagillol derivative to target sites. The polymer backbone acts as a carrier that modulates the pharmacokinetic properties and reduces systemic toxicity while maintaining therapeutic efficacy at the target site.
2Manufacturing precision
If stable intermediates are formed for polymer conjugation, then manufacturing precision is improved, but self-condensation and hydrolysis occur
Solution Approach 1:
The chemical parameters of the intermediate compounds are optimized by adjusting the carbamate linkage structure and ster The patent describes stable intermediates with specific molecular structures that resist self-condensation and hydrolysis, enabling precise polymer conjugation while maintaining chemical stability throughout the manufacturing process.
3Manufacturing precision
If impurities are removed from polymer backbone, then purity is improved, but difficulty in removal increases
Solution Approach 1:
Impurity prevention is implemented at the intermediate stage through careful control of the coupling reactions. By stabilizing the intermediates and controlling reaction conditions, impurity formation is minimized before polymerization occurs, making subsequent purification much easier and more effective.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present disclosure relates to salts and polymorphs of aminoalkylfumagillol carbamates (e.g., fumagill-6-yl N-(trans-4-aminocyclohexyl)carbamate benzenesulfonic acid salt and fumagill-6-yl N-(trans-4-aminocyclohexyl)carbamate hydroxynaphthoic acid salt). The polymorphs are characterized by X-ray powder diffraction, differential scanning calorimetry, and thermogravimetric analysis, among other methods. The polymorphs and salts can be used as intermediates in the production of fumagillol derivatives (e.g., polymer-conjugated fumagillol derivatives) as well as therapeutic agents for the treatment of various diseases and conditions such as cancer.